Potomavac (Canada)

Company: Boehringer Ingelheim Animal Health

Neorickettsia Risticii Bacterin

PHF

Potomavac Indications

This product has been shown to be effective for the vaccination of healthy horses 3 months of age or older against potomac horse fever (PHF) (equine monocytic ehrlichiosis) due to Neorickettsia risticii. The duration of immunity against PHF has not been determined. For more information regarding efficacy and safety data, go to productdata.aphis.usda.gov.

Directions and dosage: Shake well before use. For primary vaccination, aseptically administer one 1 mL dose intramuscularly into healthy horses. Administer a second dose 3 to 4 weeks later. Contact your veterinarian or the manufacturer for information on revaccination frequency.

Precautions

Store at 35-46°F (2-8°C). Do not freeze. Do not mix with other products. Use entire contents when first opened. Do not vaccinate within 21 days before slaughter. In rare instances, administration of vaccines may cause lethargy, fever, and inflammatory or hypersensitivity types of reactions. Treatment may include antihistamines, anti-inflammatories, and/or epinephrine. Vaccinating animals whose immune response is compromised by stress, disease, etc. may not produce the desired results. This product has not been tested in pregnant mares. In case of human exposure, contact a physician.

Preservatives: Gentamicin and thimerosal.

For use in animals only.

Restricted to use by or under the direction of a veterinarian.

Potomavac™ is a trademark in the USA of Boehringer Ingelheim Animal Health USA Inc.

Potomavac™ is a trademark in Canada of Boehringer Ingelheim Vetmedica GmbH, used under license.

Manufactured by:

Boehringer Ingelheim Animal Health USA Inc., Athens, GA 30601

Phone: 1 (888) 637-4251

VLN/PCN 124/2639.00

Distributed in Canada by:

Boehringer Ingelheim Animal Health Canada Inc., Burlington ON L7L 5H4

CPN: 1182019.4